Clinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases.

dc.contributor.authorRodríguez Padial, Luis
dc.contributor.authorBarón-Esquivias, Gonzalo
dc.contributor.authorHernández Madrid, Antonio
dc.contributor.authorMarzal Martín, Domingo
dc.contributor.authorPallarés-Carratalá, Vicente
dc.contributor.authorde la Sierra, Alejandro
dc.date.accessioned2025-01-07T16:17:36Z
dc.date.available2025-01-07T16:17:36Z
dc.date.issued2016-03-25
dc.description.abstractCardiovascular diseases are the leading cause of death in the world. Coronary artery diseases, atrial fibrillation or hypertensive heart disease, are among the most important cardiovascular disorders. Hypertension represents a significant risk factor for cardiovascular mortality; thus, control of high blood pressure has become a priority to prevent major complications. Although the choice of drugs for treating hypertension remains controversial, extensive clinical evidences point to calcium channel blockers as first-line agents. Diltiazem, a non-dihydropyridine calcium channel blocker, is an effective and safe antihypertensive drug, alone or in combination with other agents. Diltiazem lowers myocardial oxygen demand through a reduction in heart rate, blood pressure, and cardiac contractility, representing also a good alternative for the treatment of stable chronic angina. Furthermore, diltiazem reduces conduction in atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. In this review, clinical experts highlight studies on diltiazem effectiveness and safety for the treatment of several cardiovascular diseases and make evidence-based recommendations regarding the management of diltiazem in the clinical practice. Lacer Spain.
dc.identifier.doi10.1007/s40119-016-0059-1
dc.identifier.issn2193-8261
dc.identifier.pmcPMC4906086
dc.identifier.pmid27016085
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC4906086/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s40119-016-0059-1.pdf
dc.identifier.urihttps://hdl.handle.net/10668/27737
dc.issue.number1
dc.journal.titleCardiology and therapy
dc.journal.titleabbreviationCardiol Ther
dc.language.isoen
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.number75-82
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectAngina
dc.subjectAtrial arrhythmia
dc.subjectCalcium channel blocker (CCB)
dc.subjectDiltiazem
dc.subjectHypertension
dc.titleClinical Experience with Diltiazem in the Treatment of Cardiovascular Diseases.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number5

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC4906086.pdf
Size:
411.57 KB
Format:
Adobe Portable Document Format